The latest U.S. FDA emergency use authorizations to fall by the wayside, as COVID-19 continues to evolve, are the ones for the first Moderna Inc. and Pfizer Inc.-Biontech SE’s mRNA vaccines.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrocyte, Gritstone, GSK, Immutep, Inovio, Kiora, Minervax, Neurosense, Peptilogics, Quralis, Rallybio, Relief, Shionogi, Umecrine, Vaxcyte, Xbiotech.

Additional early-stage research and drug discovery news in brief, from: Dragonfly Therapeutics, Enanta Pharmaceuticals, Enanta Pharmaceuticals, Kura Oncology, Telix Pharmaceuticals, Tonix Pharmaceuticals.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Affini-T, Akthelia, Argenx, Athenex, Biomed, Caris, Eisai, Enzolytics, Flare, Genmab, Geovax, Gilead, Graf, Navidea, Meilleur, Nkgen, Smart Immune.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astellas, Gilead, Mindmedicine, Minghui, Ocugen, Sunstone, Travere, Zenshine.

Additional early-stage research and drug discovery news in brief, from: Bioaegis Therapeutics, Evaxion Biotech, Jubilant Therapeutics, Sana Biotechnology.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aeglea, Altamira, Atea, Avalyn, Cellectis, Junshi, Kineta, Leap, Merck KGaA, Mymd, Novaliq, Onl, Panbela, Scineuro, Sirnaomics, Verrica.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acelyrin, Airway, Altimmune, Bavarian, Chinook, Genexine, Hibio, Hotspot, Humacyte, Maia, Moderna, Paradigm, Quadriga.

Research at Pardes Biosciences Inc. has led to the identification of cysteine protease inhibitors, particularly 3C-like proteinase (3CLpro, Mpro, nsp5; SARS-CoV-2) and Mpro (HCoV-229E virus) inhibitors, reported to be useful for the treatment of viral infections.